Search

Displaying results 5421 - 5430 of 10000 in total
  1. Drug

    Shark liver oil

    go.drugbank.com/drugs/DB11088
    Approved

    The potential benefit of shark oil has been experimented in different therapeutic implications, where it is claimed to improve immune responses and exert an antitumor activity. … Shark oil is a rich source of alkylglycerols and squalene, with relatively low amounts of n-3 polyunsaturated fatty acids.

  2. Drug

    Zimelidine

    go.drugbank.com/drugs/DB04832
    ApprovedWithdrawn

    Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients.

  3. Drug

    PEV3A

    go.drugbank.com/drugs/DB05144
    Investigational

    PEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. It is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302. … The elicited antibodies are highly specific and able to inhibit the parasite’s ability to invade liver tissue _in vitro_.

  4. Drug

    Cocarboxylase

    go.drugbank.com/drugs/DB01987
    ApprovedInvestigational

    The coenzyme form of Vitamin B1 present in many animal tissues. It is a required intermediate in the pyruvate dehydrogenase complex and the ketoglutarate dehydrogenase complex.

  5. Drug

    Dexchlorpheniramine

    go.drugbank.com/drugs/DB13679
    Investigational

    It is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells. … Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine.

  6. Drug

    Thymol

    go.drugbank.com/drugs/DB02513
    ApprovedInvestigational

    It is used as a stabilizer in pharmaceutic preparations. It has been used for its antiseptic, antibacterial, and antifungal actions, and was formerly used as a vermifuge. (Dorland, 28th ed)

  7. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. … Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases.

  8. Drug

    Lesopitron

    go.drugbank.com/drugs/DB04970
    Experimental

    Lesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.

  9. Drug

    Veltuzumab

    go.drugbank.com/drugs/DB05656
    Investigational

    Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.

  10. Drug

    Mephenytoin

    go.drugbank.com/drugs/DB00532
    ApprovedWithdrawn

    Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. … These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha.